Results 1 to 10 of about 605,792 (294)

²²⁵Ac-Labeled Somatostatin Analogs in the Management of Neuroendocrine Tumors: From Radiochemistry to Clinic [PDF]

Pharmaceutics, 2023
The widespread use of peptide receptor radionuclide therapy (PRRT) represents a major therapeutic breakthrough in nuclear medicine, particularly since the introduction of 177Lu-radiolabeled somatostatin analogs. These radiopharmaceuticals have especially
Léa Rubira, Emmanuel Deshayes, Lore Santoro, Pierre Olivier Kotzki, Cyril Fersing   +4 more
doaj   +3 more sources

Overview of Radiolabeled Somatostatin Analogs for Cancer Imaging and Therapy [PDF]

Molecules, 2020
Identified in 1973, somatostatin (SST) is a cyclic hormone peptide with a short biological half-life. Somatostatin receptors (SSTRs) are widely expressed in the whole body, with five subtypes described. The interaction between SST and its receptors leads
Romain Eychenne, Christelle Bouvry, Mickael Bourgeois, Pascal Loyer, Eric Benoist, Nicolas Lepareur   +5 more
doaj   +3 more sources

Treatment with somatostatin analogs induces differentially expressed let-7c-5p and mir-3137 in small intestine neuroendocrine tumors [PDF]

BMC Cancer, 2019
Background Distant metastases frequently occur in gastroenteropancreatic neuroendocrine tumors. If hepatic surgery is not feasible, patients are treated with somatostatin analogs.
Florian Bösch, Alexandr V. Bazhin, Sabine Heublein, Katharina Brüwer, Thomas Knösel, Florian P. Reiter, Christoph J. Auernhammer, Markus O. Guba, Christine Spitzweg, Jens Werner, Martin K. Angele   +10 more
doaj   +3 more sources

Insights into Structure-Activity Relationships of Somatostatin Analogs Containing Mesitylalanine [PDF]

Molecules, 2013
The non-natural amino acid mesitylalanine (2,4,6-trimethyl-L-phenylalanine; Msa) has an electron-richer and a more conformationally restricted side-chain than that of its natural phenylalanine counterpart.
Pablo Martín-Gago, Eric Aragón, Marc Gomez-Caminals, Jimena Fernández-Carneado, Rosario Ramón, Pau Martin-Malpartida, Xavier Verdaguer, Pilar López-Ruiz, Begoña Colás, María Alicia Cortes, Berta Ponsati, Maria J. Macias, Antoni Riera   +12 more
doaj   +4 more sources

Somatostatin analogs: Clinical application in relation to human somatostatin receptor subtypes [PDF]

Biochemical Pharmacology, 1995
Although in situ hybridization has been used to examine the distribution of messenger RNA for somatostatin receptor subtypes (sst) in human tumors, the cellular localization of sst1 and sst2A receptors has not been ...
Hofland, L.J. (Leo), Lamberts, S.W.J. (Steven), Visser-Wisselaar, H.A. (Heleen)   +2 more
core   +27 more sources

Treatment Patterns of Long-Acting Somatostatin Analogs for Neuroendocrine Tumors [PDF]

Journal of Health Economics and Outcomes Research, 2023
# Background Long-acting somatostatin analog therapy (LA-SSA) is recommended as first-line therapy for treatment of unresectable or metastatic neuroendocrine tumors (NETs). Understanding treatment sequencing and dosing patterns of LA-SSA is essential for
Callisia N. Clarke, Paul Cockrum, Thomas J.R. Beveridge, Michelle Jerry, Donna McMorrow, Anh Thu Tran, Alexandria T. Phan   +6 more
doaj   +2 more sources

Acromegaly: Pathophysiological Considerations and Treatment Options Including the Evolving Role of Oral Somatostatin Analogs. [PDF]

Pathophysiology, 2023
Daniel CP, Wagner MJ, Borne GE, Plaisance CJ, Ahmadzadeh S, Aquino A, Shekoohi S, Kaye AM, Cornett EM, Kaye AD.   +9 more
europepmc   +3 more sources

A case of malignant insulinoma responsive to somatostatin analogs treatment [PDF]

BMC Endocrine Disorders, 2018
Background Insulinoma is a rare tumour representing 1–2% of all pancreatic neoplasms and it is malignant in only 10% of cases. Locoregional invasion or metastases define malignancy, whereas the dimension (> 2 cm), CK19 status, the tumor staging and ...
Mariasmeralda Caliri, Valentina Verdiani, Edoardo Mannucci, Vittorio Briganti, Luca Landoni, Alessandro Esposito, Giulia Burato, Carlo Maria Rotella, Massimo Mannelli, Alessandro Peri   +9 more
doaj   +2 more sources

Somatostatin analogs: Future directions [PDF]

Metabolism, 1996
Herder, W.W. (Wouter) de, Hofland, L.J. (Leo), Lamberts, S.W.J. (Steven), Lely, A-J. (Aart-Jan) van der   +3 more
core   +4 more sources

Radiomics in advanced gastroenteropancreatic neuroendocrine neoplasms: Identifying responders to somatostatin analogs. [PDF]

J Neuroendocrinol
Polici M, Caruso D, Masci B, Marasco M, Valanzuolo D, Dell'Unto E, Zerunian M, Campana D, De Santis D, Lamberti G, Iannicelli E, Prosperi D, Annibale B, Laghi A, Panzuto F, Rinzivillo M.   +15 more
europepmc   +3 more sources